

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
11 August 2022 (11.08.2022)



(10) International Publication Number
WO 2022/167460 A1

(51) International Patent Classification:

C07K 16/18 (2006.01) *A61K 39/395* (2006.01)
C07K 16/28 (2006.01) *A61P 35/00* (2006.01)

(21) International Application Number:

PCT/EP2022/052425

(22) International Filing Date:

02 February 2022 (02.02.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

21154786.4 02 February 2021 (02.02.2021) EP
PCT/EP2021/087618
23 December 2021 (23.12.2021) EP

(71) Applicant: **NUMAB THERAPEUTICS AG** [CH/CH];
Einsiedlerstrasse 34, 8820 Wädenswil (CH).

(72) Inventors: **CHATTERJEE, Bithi**; Mattenhof 33, 8051
Zurich (CH). **SNELL, Daniel**; Im Sunnebüel 8, 8800 Thal-
wil (CH). **SIMONIN, Alexandre**; 5 rue de l'Au, 68128
Rosenau (FR). **GUNDE, Tea**; Turbinenstrasse 33, 8005
Zurich (CH). **HESS, Christian**; Uetlibergstrasse 304, 8045
Zurich (CH). **WARMUTH, Stefan**; Zopfstrasse 28, 8804
Au (CH). **BROCK, Matthias**; Feldstrasse 46, 8904 Aesch
(CH). **TIETZ, Julia**; Bundentalstrasse 1, 8952 Schlieren
(CH). **JOHANSSON, Maria**; Route du Lac 7, 1026 Denges
(CH). **SPIGA, Fabio Mario**; Käpfnerweg 28, 8810 Horgen
(CH).

(74) Agent: **WALLINGER RICKER SCHLOTTER TOST-
MANN PATENTANWÄLTE**; Zweibrückenstraße 5-7,
80331 München (DE).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN,
KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD,
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO,
NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW,
SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,

GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))
— with sequence listing part of description (Rule 5.2(a))

WO 2022/167460 A1

(54) Title: MULTISPECIFIC ANTIBODIES HAVING SPECIFICITY FOR ROR1 AND CD3

(57) Abstract: The present invention relates to a multispecific antibody comprising one or two binding domains, which specifically bind to the extracellular domain of ROR1 (ROR1-BDs), and one binding domain, which specifically binds to CD3 (CD3-BD), wherein the multispecific antibody does not comprise an immunoglobulin Fc region. The present invention further relates to nucleic acids encoding said multispecific antibody, vector(s) comprising said nucleic acids, host cell(s) comprising said nucleic acids or said vector(s), and a method of producing said multispecific antibody. Additionally, the present invention relates to pharmaceutical compositions comprising said multispecific antibody and methods of use thereof.